高级检索
    张必翔, 邹威. 仑伐替尼联合TACE辅助治疗术后高复发风险肝细胞癌患者: LANCE研究结果更新[J]. 循证医学, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
    引用本文: 张必翔, 邹威. 仑伐替尼联合TACE辅助治疗术后高复发风险肝细胞癌患者: LANCE研究结果更新[J]. 循证医学, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
    shu
    ZHANG Bi-xiang, ZOU Wei. Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
    Citation: ZHANG Bi-xiang, ZOU Wei. Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
    shu

    仑伐替尼联合TACE辅助治疗术后高复发风险肝细胞癌患者: LANCE研究结果更新

    Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study

      摘要
      • HTML全文
      • 参考文献(3)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回